Ischemic heart disease (IHD) is a major cause of mortality and morbidity worldwide. It caused 1 of every 6 deaths in the United States in 2008. Patients with serious IHD are usually presented with large areas of myocardial infarction affecting the cardiac functions and may even cause ischemic cardiomyopathy and heart failure. The efficacy of coronary artery bypass grafting (CABG) surgery alone for these patients is unclear. However, the field of myocardial regeneration utilizing novel bone marrow stem cell (BMSC) therapy may prove to play an important role in the future of IHD management. Promising results of preclinical and experimental studies have led to several clinical trials evaluating the feasibility, safety, and efficacy of combining CABG with BMSC therapy in treating patients with serious IHD. This systematic review discusses different methods of BMSCs delivery, their potential mechanism of action, and types.